EUCTR2013-003774-27-GB进行中（未招募）1 期
An open label, randomised, two-way crossover scintigraphic study to investigate lung deposition of radiolabelled OligoG delivered as a dry powder and as a nebulised solution in cystic fibrosis patients - A study to investigate lung deposition of radiolabelled OligoG (v1.0)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Aged at least 18 years at screening.
- •2.Understands and is willing, able and likely to comply with all study procedures and restrictions.
- •3.Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent (signed and dated) obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.)
- •4.Male or female with a confirmed diagnosis of cystic fibrosis defined by:
- •i.Clinical features consistent with the diagnosis of cystic fibrosis (Rosenstein et al., 1998); AND
- •ii.Sweat chloride = 60 mmol/L by pilocarpine iontophoresis; OR
- •iii.Genotypic confirmation of 2 CF-causing mutations
- •5.Positive microbiological finding of Pseudomonas aeruginosa (mucoid or nonmucoid) in expectorated sputum (and/or swab) documented within the last 24 months prior to screening. Negative finding is acceptable provided the proportion of patients with positive findings is at least 80% as possible.
- •6.At screening, FEV1 must be between 35 and 80% of the predicted normal value following adjustment for age, gender and height according to the Knudson equation (Knudson et al., 1983)
- •7.Be clinically stable in the opinion of the referring physician at the CF unit.
- •8.Female subjects of child-bearing potential and male subjects participating in the study who are sexually active must use acceptable contraception. Female subjects documented as being of non-child bearing potential are exempt from the contraceptive requirements. For the purpose of this study, acceptable contraception is defined as:
- •i.Oral, injected or implanted hormonal methods or contraception; OR
- •ii.Placement of an intrauterine device (IUD) or intrauterine system (IUS); OR
- •iii.Barrier methods of contraception: condom or occlusive cap with spermicidal foam/gel/film/cream/suppository
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 12
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1.On-going acute illness. Patients must not have needed an outpatient visit, hospitalisation or required any change in therapy for other pulmonary disease between screening and AV1.
- •2.History of, or planned organ transplantation.
- •3.Requirement for continuous (24 hour/day) oxygen supplementation.
- •4.Concomitant administration of inhaled mannitol or hypertonic saline within 48 hours of Period 1, Day 1.
- •5.Clinically significant abnormal findings on haematology or clinical chemistry. In addition, any value = 3 x the upper limit of normal will exclude the patient from participating in the study.
- •6.Patients unable to perform pulmonary function tests according to ATS criteria.
- •7.Pregnant or breast-feeding women. A negative pregnancy test must be demonstrated in females of child-bearing potential at screening.
- •8.Patients who have participated in any interventional clinical trial within the 28 days prior to AV1.
- •9.Patients with documented or suspected, clinically significant, alcohol or drug abuse. The determination of clinical significance will be made by the study physician.
- •10.Known allergies or intolerances to alginates.
- •11.Any active malignant disease (with the exception of basal cell carcinoma; BCC).
- •12.Any serious or active medical or psychiatric illness, which in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol.
- •13.Haemoptysis more than 60 mL at any time within 30 days before study drug administration.
- •14.Patients for whom participation in this study will exceed the limits of total radiation exposure allowed in any 12 month period (5 mSv), or will exceed 10 mSv over any three year period.
- •15.Male patients who are intending to father a child in the 3 months following the study or are unwilling to abstain from sexual intercourse with pregnant or lactating women. Female patients who are intending to become pregnant in the 3 months following the study.
- •16.Patients who have any non-removable metal objects such as metal plates, screws etc in their head, neck, chest or abdominal area.
- •17.As a result of a physical examination or screening investigations, the physician responsible considers the patient unfit for the study.
研究者
相似试验
已完成
1 期
A Randomized, Open Label, Cross-over Scintigraphic Evaluation of Lung Deposition of Alpha1-Proteinase Inhibitor (Human) (A1-PI(H) Inhalation Solution) using Two Inhalation Modes of the I-neb® Nebulizer in Healthy Subjects and Subjects with Cystic FibrosisE84Cystic FibrosisCystic fibrosisDRKS00000754CSL Behring21
进行中（未招募）
不适用
A randomised open label, six way, cross-over scintigraphic evaluation of the effect of inspiratory flow rate on lung and oropharyngeal deposition with the Respimat(R) inhaler vs a Metered Dose Inhaler (HFA-MDI) using Berodural(R) in patients with Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD) is characterised by airflow limitation and bronchial inflammation. Clinically, COPD is characterised by progressive dyspnoea on exertion and intermittent exacerbations, usually precipitated by infection. Airflow limitation results from one or more different processes including smooth muscle spasm, mucosal oedema, loss of elastic recoil, inspissated mucus and cellular debris in airway lumen, and thickening of the bronchial wall.MedDRA version: 8.0Level: LLTClassification code 10010952EUCTR2005-000841-12-DEBoehringer Ingelheim Pharma GmbH & Co. KG18
已完成
不适用
Evaluation of Pharmacokinetic/Pharmacodynamic Properties and Safety of Leucostim® Compared to Neupogen® in Healthy Adult VolunteersDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0001861Dong-A ST56
已完成
1 期
A randomized, open-label and two-way crossover study to evaluate the effects of SIR1-365 after a single oral dose of 300 mg on the activities of CYP450 isoform 3A in healthy young subjectsACTRN12621000400864Sironax Australia Pty Ltd20
尚未招募
1 期
Open label, randomized, two-way crossover, two-sequence, two-period, two-treatment study of 750 mg levofloxacin tablet in healthy Thai volunteersHealthy volunteersTCTR20161129005International Bio Service28